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and 94.4%, respectively) in Henan 
Province were higher than the average 
levels (10.2%, 62.5%, respectively) 
reported by a worldwide study (10). 
Pyrazinamide is an essential drug 
recommended by World Health 
Organization guidelines for treatment 
of MDR TB. Among the population 
with MDR TB that we studied, 10 
(76.9%) of 13 XDR isolates were 
sensitive to pyrazinamide (data not 
shown), suggesting that pyrazinamide 
is still an effective fi rst-line anti-TB 
drug for most XDR TB patients in 
Henan Province.
We restricted our investigation 
to 1 province. However, given the 
average national prevalence of XDR 
TB (8% of MDR TB) (1) and the 
magnitude of the population of Henan 
Province, our fi ndings indicate that 
the prevalence of XDR TB might be 
higher in central China than previously 
documented.
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Seroprevalence of 
Pandemic Infl uenza 
Viruses, New York, 
New York, USA, 
2004
To the Editor: Exposures to 
infl uenza viruses can lead to immune 
responses that substantially affect 
susceptibility to infection with 
related viruses. Characterization 
of preexisting immunity within a 
population can inform public health, 
as highlighted during the infl uenza 
A(H1N1)pdm09 virus pandemic, 
when surveillance data demonstrated 
that older persons (>65 years old) 
were less likely than younger persons 
to have infl uenza (1). Seroprevalence 
studies of prepandemic samples show 
that older persons had preexisting 
antibody responses to A(H1N1)
pdm09 virus, presumably because of 
prior exposure to related strains (2). 
The A(H1N1)pdm09 virus possesses 
hemagglutinin and neuraminidase 
genes derived from classical swine 
infl uenza virus (3).
Epidemiologic and molecular 
data indicate that prior exposure to 
early twentieth century H1N1 viruses 
conferred immunity to A(H1N1)
pdm09 virus. Human antibodies that 
neutralize A(H1N1)pdm09 virus and 
H1N1 subtype viruses from earlier 
in the twentieth century have been 
characterized, and animal studies have 
demonstrated that antibodies to the 
earlier H1N1 subtype viruses cross-
neutralize A(H1N1)pdm09 virus and 
protect from virus challenge (2,4–6). 
Prior exposure to antigenically related 
viruses can explain the relationship 
between age and susceptibility to 
infection.
To determine the seroprevalence 
of preexisting hemagglutinin inhibition 
(HAI) antibody titers to infl uenza 
strains with pandemic potential, we 
tested serum samples for antibodies to 
A(H1N1)pdm09 virus and the 1918, 
1957, and 1968 pandemic viruses. 
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The samples had been collected in 
2004 from a representative sample 
of adults in New York City (NYC), 
USA, as part of the NYC Health and 
Nutrition Examination Survey (online 
Technical Appendix, wwwnc.cdc.
gov/EID/pdfs/12-0156-Techapp.pdf). 
For the 1918 and A(H1N1)pdm09 
viruses, the highest prevalence of 
HAI titers >40 was among persons 
born before 1940 (>65 years old in 
2004), although younger adults also 
had antibodies. Antibody prevalence 
to the 1957 H2N2 subtype virus was 
highest among persons born during 
1942–1961, and >70% in persons 
born before 1971 had antibody 
to the 1968 H3N2 subtype virus 
(Figure). For all pandemic viruses, 
there was no signifi cant difference in 
seroprevalence by sex or by US birth 
and only minor differences by race/
ethnicity (online Technical Appendix 
Table 1).
We examined A(H1N1)pdm09 
virus seroprevalence by the age of 
persons tested and by antibody titer. 
The mean age for persons with no 
serologic evidence of prior exposure 
(titer <20) was 50 years, compared 
with 72 years for those with titers 
of 20–40 and 80 years for those with 
titers >40 (online Technical Appendix 
Table 2). In a multivariate logistic 
regression model, presence of antibody 
to the 1918 H1N1 subtype virus was 
strongly associated with antibody 
to A(H1N1)pdm09 virus (online 
Technical Appendix Table 3). No 
demographic factor was independently 
associated with positivity to A(H1N1)
pdm09 virus. By using a nonlinear 
regression model for the probability of 
A(H1N1)pdm09 antibody prevalence 
compared with birth year, we found 
the model that best fi t the age-stratifi ed 
seroprevalence data infl ected near 1927 
(online Technical Appendix Figure), 
indicating that persons born before 
1927 were most reliably protected.
Our fi ndings show that the 
prevalence of pandemic infl uenza 
virus antibody in a representative 
population-based 2004 sample of NYC 
residents correlated with birth year and 
year(s) of circulating virus. These data 
reveal the immunologic background 
during the emergence of A(H1N1)
pdm09 virus in NYC beginning in 
late April 2009 (7) and help explain 
why fewer cases of A(H1N1)pdm09 
infection were detected among 
older persons than younger persons, 
supporting the conclusion that the 
difference was a result of, at least in 
part, antibodies elicited by prior H1N1 
subtype infection in older persons.
Viruses antigenically resembling 
the 1918 pandemic strain circulated 
among humans earlier in the twentieth 
century; cross-reactivity with antibodies 
to those viruses likely provided 
protection against the 1918 virus. 
Most (2,4), but not all (8), previous 
A(H1N1)pdm09 virus seroprevalence 
studies demonstrated an increase in 
immunity with age. In our study, more 
persons born before than after 1927 
(i.e., persons >82 vs. those 65–82 
years of age in 2009) had HAI assay 
results positive for A(H1N1)pdm09 
virus. Protection among persons 65–82 
years old during the 2009 pandemic 
may be explained by the presence of 
preexisting immunity not measured 
by standard HAI tests (e.g., antibodies 
that target the hemagglutinin stalk) or 
by T-cell responses (9). More positive 
test results were recorded with the 
1918 than the A(H1N1)pdm09 virus; 
this fi nding is consistent with the 
model in which preexisting immunity 
to A(H1N1)pdm09 virus was derived 
from exposure to the 1918 pandemic 
strain or to antigenically related 
strains that evolved since then (10). 
The 1918 and 2009 strains used in 
testing may have exhibited different 
sensitivities in HAI assays. Immunity 
in older populations is not surprising 
and was seen in the 1918, 1957, and 
1968 pandemics, during which newly 
introduced pandemic viruses were 
more likely to cause clinical illness in 
younger persons, presumably because 
prior exposure to similar viruses 
resulted in cross-reactive antibodies 
(11).
Study limitations include a 
relatively small sample size and a lack 
of history regarding infl uenza virus 
infection or vaccination. Nevertheless, 
the ability to evaluate seroreactivity in 
a representative sample of adults helps 
validate and reinforce previously 
published fi ndings on H1N1 subtype 
viruses and clarifi es levels of immunity 
to H2N2 and H3N2 subtype viruses.
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Figure. Seroprevalence of cross-reactive antibodies to the 1918, 1957, 1968, and 2009 
pandemic infl uenza viruses among persons >23 years of age, New York, New York, 2004. 
LOESS (locally weighted scatterplot smoothing) curves represent the estimated prevalence 
of hemagglutination-inhibition antibody titers of >40 (positive titers) by year of birth.
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Infection in Patient 
with Sarcoidosis, 
France, 2012
To the Editor: Streptomyces spp. 
are aerobic, gram-positive bacteria 
of the order Actinomycetales, known 
for their ability to produce antimicro-
bial molecules such as streptomycin. 
Streptomyces spp., usually sapro-
phytic to humans, can cause local cu-
taneous fi stulized nodules known as 
actinomycetoma or mycetoma. Severe 
invasive infections have seldom been 
reported, but most cases reported have 
occurred in immunocompromised pa-
tients (1–5). We report a case of inva-
sive pulmonary infection caused by a 
Streptomyces sp. in a splenectomized 
patient with sarcoidosis.
In 2003, multiorgan sarcoidosis 
was diagnosed in a man, 57 years of 
age; the disease involved lungs, skin, 
joints, and lymph nodes. Corticoste-
roids were initially given but quickly 
discontinued because of a severe psy-
chiatric reaction. In 2007, a splenec-
tomy was performed on this patient 
to remove an intestinal obstruction 
caused by a severely enlarged spleen, 
identifi ed as a specifi c localization of 
sarcoidosis.
In April 2008, the patient was 
admitted to the internal medicine unit 
of Saint-André Hospital in Bordeaux, 
France with fever (38.9°C/102°F), 
progressive asthenia, anorexia, weight 
loss, productive cough, and New York 
Heart Association grade III dyspnea. 
Bilateral basal crackles could be heard 
in the lungs; physical examination 
fi ndings were otherwise within nor-
mal limits. Biological tests showed 
infl ammatory syndrome with elevated 
C-reactive protein (74 mg/L, reference 
value <5 mg/L) without any other 
consequential abnormality. Gamma 
globulin levels were normal. A chest 
radiograph showed bilateral intersti-
tial infi ltrate. A computed tomogra-
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, 
outbreaks, or original research are 
welcome. Letters commenting on ar-
ticles should contain no more than 
300 words and 5 references; they are 
more likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.
